期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 2, 页码 481-484出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI61345
关键词
-
资金
- NIAID NIH HHS [R37AI044628, R01 AI081848, R37 AI044628, R01AI081848] Funding Source: Medline
Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据